HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
UTHR
United Therapeutics Corporation
UTHR's fundamentals are mixed, but it looks expensive: trading at 22x earnings, above its usual 16x. Its downside scenario is about four times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
UTHR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
UTHR's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
UTHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $321 | -46% |
| Fair | 16x | $423 | -29% |
| Expensive | 19x | $511 | -14% |
| Current | 22x | $593 | — |
| Forward | 25x | $593 | — |
Historical ranges are pointers, not guarantees.
UTHR's PE is in its expensive range at 22x. Analysts expect earnings to fall, which would put today's price at 25x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over UTHR on the outlook, with more favorable revenue and profitability expectations.
UTHR Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect UTHR's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
UTHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.18 | -8.6% |
| Q3 2026 | $26.46 | +0.1% |
| Q2 2026 | $27.91 | +8.8% |
| Q1 2026 | $27.05 | +7.8% |
| Q4 2025 | $27.86 | +13% |
| Q3 2025 | $26.43 | +16% |
| Q2 2025 | $25.66 | +18% |
| Q1 2025 | $25.10 | +19% |
| Q4 2024 | $24.64 | +24% |
UTHR has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over UTHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
UTHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $832.5M | +4.1% |
| Q2 2026 | $783.3M | -1.9% |
| Q1 2026 | $781.5M | -1.6% |
| Q4 2025 | $790.2M | +7.4% |
| Q3 2025 | $799.5M | +6.8% |
| Q2 2025 | $798.6M | +12% |
| Q1 2025 | $794.4M | +17% |
| Q4 2024 | $735.9M | +20% |
UTHR's revenue has held roughly level: $833M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | -12 points |
| Q2 2026 | 42% | -3.4 points |
| Q1 2026 | 42% | -6.5 points |
| Q4 2025 | 45% | -3.5 points |
| Q3 2025 | 49% | +2.8 points |
| Q2 2025 | 46% | +0.9 points |
| Q1 2025 | 48% | -4.4 points |
| Q4 2024 | 49% | +6.3 points |
UTHR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over UTHR on cash flow, with more consistent year-over-year improvement.
UTHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $125.8M | -64% |
| Q2 2026 | $205.6M | +59% |
| Q1 2026 | $362.5M | -6.2% |
| Q4 2025 | $173.3M | -32% |
| Q3 2025 | $351.6M | +17% |
| Q2 2025 | $129.5M | -31% |
| Q1 2025 | $386.3M | +14% |
| Q4 2024 | $254.5M | +253% |
UTHR's free cash flow has been positive every quarter for seven years: $867M over the past year, down 23% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over UTHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
UTHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -500K shares |
| 1 year | -4.2% | -2M shares |
| 3 years | -8.9% | -4.4M shares |
| 5 years | -4.8% | -2.3M shares |
| Available history | +3.4% | +1.5M shares |
UTHR has 45M diluted shares, down 4.2% from a year ago, with $2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | — |
| Q1 2026 | $1.5B |
| Q4 2025 | — |
| Q3 2025 | $1B |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
UTHR spent $2B buying back its own shares over the past year, up 100% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
UTHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.2x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -1.0x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
UTHR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
UTHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.5 | Neutral |
| Stochastic | 80.5 | Overbought |
UTHR's weekly RSI is 61 (neutral) and its Stochastic is 81 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
UTHR PE vs Healthcare Sector
| Metric | UTHR | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 13% below |
| PE % | 100 | 29 | 71 pts above |
UTHR is trading at 22x earnings, a 13% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
UTHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $555.1 | 6.9% above |
| 20 week MA | $533.6 | 11% above |
| 50 week MA | $527.2 | 13% above |
| 100 week MA | $438.2 | 35% above |
| 200 week MA | $351.1 | 69% above |
UTHR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
UTHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.8 | $149.8 | +69% |
| 2021 | $149.8 | $214.0 | +43% |
| 2022 | $214.0 | $278.8 | +30% |
| 2023 | $278.8 | $219.9 | -21% |
| 2024 | $219.9 | $360.0 | +64% |
| 2025 | $360.0 | $507.2 | +41% |
| 2026 YTD | $507.2 | $593.3 | +17% |
UTHR has the edge over HIMS on returns for 2026, with the stronger performance.